{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:33:35Z","timestamp":1783449215946,"version":"3.55.0"},"reference-count":319,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbcan.2025.189493","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:42:44Z","timestamp":1762645364000},"page":"189493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma"],"prefix":"10.1016","volume":"1880","author":[{"given":"Yiming","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10272","key":"10.1016\/j.bbcan.2025.189493_bb0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41408-024-01190-9","article-title":"Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma","volume":"14","author":"Nakamoto-Matsubara","year":"2024","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0025","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"9","author":"Mahindra","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2025.189493_bb0040","doi-asserted-by":"crossref","first-page":"1243997","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112597","article-title":"Epigenetic crosstalk between malignant plasma cells and the tumour microenvironment in multiple myeloma","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0055","first-page":"OF1","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US myeloma immunotherapy consortium","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.bbcan.2025.189493_bb0060","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-025-01334-5","article-title":"Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma","volume":"15","author":"Golmohammadi","year":"2025","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40364-025-00803-0","article-title":"Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0080","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European myeloma network","volume":"12","author":"van de Donk","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbcan.2025.189493_bb0085","first-page":"13 (3)","article-title":"Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","author":"Jin","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2022.05.015","article-title":"Cancer vaccines","volume":"40","author":"Schiller","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189493_bb0095","first-page":"21 (14)","article-title":"Immunotherapies and combination strategies for Immuno-oncology","author":"Barbari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189493_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10432","key":"10.1016\/j.bbcan.2025.189493_bb0105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/d41573-021-00110-x","article-title":"COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cac2.70002","article-title":"Breaking barriers: smart vaccine platforms for cancer immunomodulation","volume":"45","author":"Gomari","year":"2025","journal-title":"Cancer Commun (Lond)"},{"issue":"29","key":"10.1016\/j.bbcan.2025.189493_bb0125","doi-asserted-by":"crossref","first-page":"18801","DOI":"10.1021\/acsnano.4c05065","article-title":"Components, formulations, deliveries, and combinations of tumor vaccines","volume":"18","author":"Liu","year":"2024","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189493_bb0135","doi-asserted-by":"crossref","unstructured":"Zhang, T. Y.; Xu, H.; Zheng, X. N.; Xiong, X. Y.; Zhang, S. Y.; Yi, X. Y.; Li, J.; Wei, Q.; Ai, J. Z. Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: a meta-analysis. MedComm (2020) 2023, 4 (4), e286. DOI: https:\/\/doi.org\/10.1002\/mco2.286.","DOI":"10.1002\/mco2.286"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0140","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras Lauren","year":"2016","journal-title":"Ca-A Cancer Journal For Clinicians"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0145","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189493_bb0150","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-025-01723-0","article-title":"Development and validation of a prognostic staging system for primary plasma cell leukemia","volume":"18","author":"Tian","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189493_bb0160","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.2019846782","article-title":"Monoclonal gammopathy of undetermined significance","volume":"133","author":"Mouhieddine","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010130","article-title":"Risk stratification and treatment in smoldering multiple myeloma","volume":"11","author":"Lussier","year":"2021","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.bbcan.2025.189493_bb0170","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1056\/NEJMc1104560","article-title":"Cosimi benedict. Multiple myeloma","volume":"364","author":"Spitzer Thomas","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0175","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel Rebecca","year":"2025","journal-title":"CA: ancer J. Clin."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189493_bb0180","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","volume":"43","author":"Kaiser","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-025-01264-2","article-title":"Venetoclax-based treatment combinations in relapsed\/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes","volume":"15","author":"Bolarinwa","year":"2025","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189493_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2015.06.003","article-title":"Risk factors for multiple myeloma: a systematic review of Meta-analyses","volume":"15","author":"Sergentanis","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0195","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40364-025-00799-7","article-title":"Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential","volume":"13","author":"Kotulova","year":"2025","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0205","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13046-024-03248-9","article-title":"Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management","volume":"43","author":"Bruno","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0210","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0215","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0220","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189493_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104913","article-title":"Next-generation immunotherapy in relapsed\/refractory multiple myeloma: strategies to achieve sustained MRD negativity","volume":"214","author":"Zhu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0230","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000003655","article-title":"Redefining multiple myeloma treatment: advances, challenges, and future directions in immunotherapy","author":"Fu","year":"2025","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0235","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0240","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/s41375-025-02677-5","article-title":"The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0245","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0250","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2025.189493_bb0255","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/ITT.S534784","article-title":"T cells dysfunction in multiple myeloma","volume":"14","author":"Cai","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.bbcan.2025.189493_bb0260","doi-asserted-by":"crossref","first-page":"1346211","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0265","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0270","first-page":"21 (14)","article-title":"Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma","author":"Akhtar","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0275","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0285","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0290","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0300","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0310","first-page":"3784","article-title":"TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells","volume":"181","author":"Rossana","year":"2008","journal-title":"J. Immunolo. (Baltimore, Md.\u202f: 1950)"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0315","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00262-022-03365-4","article-title":"Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages","volume":"72","author":"Ehlers","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0320","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/jcmm.13554","article-title":"Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease","volume":"22","author":"Jiang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0325","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2025.189493_bb0330","doi-asserted-by":"crossref","first-page":"1575509","DOI":"10.3389\/fimmu.2025.1575509","article-title":"Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential","volume":"16","author":"Jordan","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00262-014-1623-y","article-title":"Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells","volume":"64","author":"Andre","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0340","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0345","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression","volume":"36","author":"Dahlhoff","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2025.189493_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106709","article-title":"Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma","volume":"110","author":"Sun","year":"2021","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0355","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjh.18708","article-title":"Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma","volume":"201","author":"Li","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0360","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3390\/curroncol30070455","article-title":"Tumor-associated macrophages in multiple myeloma: key role in disease biology and potential therapeutic implications","volume":"30","author":"Cencini","year":"2023","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-019-0797-3","article-title":"Myeloid-derived suppressor cells in hematological malignancies: friends or foes","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189493_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204717","article-title":"Increased Monocytic myeloid-derived suppressor cells in whole blood predict poor prognosis in patients with plasma cell myeloma","volume":"10","author":"Bae","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0375","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/10245332.1998.11746409","article-title":"The role of allogeneic transplantation in the treatment of multiple myeloma","volume":"3","author":"Majolino","year":"1998","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010055","article-title":"Allogeneic stem cell transplantation in multiple myeloma","volume":"14","author":"Greil","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189493_bb0385","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0390","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma: is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0395","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3904\/kjim.2018.325","article-title":"Cellular immunotherapy in multiple myeloma","volume":"34","author":"Vo","year":"2019","journal-title":"Korean J. Intern. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0400","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","article-title":"Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0410","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1038\/s41467-025-59818-8","article-title":"Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation","volume":"16","author":"Kimman","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0415","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0420","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0425","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI","volume":"4","author":"Garfall","year":"2019","journal-title":"Insight"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0430","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"Journal of Cellular Immunotherapy"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0435","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0440","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","article-title":"Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189493_bb0445","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10297","key":"10.1016\/j.bbcan.2025.189493_bb0450","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0455","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0460","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-025-00643-6","article-title":"Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting","volume":"14","author":"Hu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0465","first-page":"11 (3)","article-title":"Adoptive cellular therapy for multiple myeloma using CAR- and TCR-transgenic T cells: response and resistance","author":"Fuchsl","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189493_bb0470","first-page":"12 (9)","article-title":"Targeting epigenetic regulation and post-translational modification with 5-Aza-2\u2032 deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy","author":"Kroonen","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0475","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.ymthe.2025.02.035","article-title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells","volume":"33","author":"Wachsmann","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2025.189493_bb0480","unstructured":"Andrade Val\u00e9ria C C; Vettore Andr\u00e9 L;Felix Roberta S,et al.Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008-02-01;8:2."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0485","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"issue":"6481","key":"10.1016\/j.bbcan.2025.189493_bb0490","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189493_bb0495","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer Mohamed","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189493_bb0500","article-title":"Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors","volume":"9","author":"Gerber","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0505","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0510","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189493_bb0515","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2025.189493_bb0520","first-page":"42","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody","volume":"136","author":"Cohen","year":"2020","journal-title":"Relapsed\/Refractory Multiple Myeloma. Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091454","article-title":"Emerging role of chimeric antigen receptor-natural killer cells for the treatment of hematologic malignancies","volume":"17","author":"Testa","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0530","doi-asserted-by":"crossref","first-page":"2546443","DOI":"10.1080\/2162402X.2025.2546443","article-title":"Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies","volume":"14","author":"Schindler-Wnek","year":"2025","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb0535","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0540","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0545","doi-asserted-by":"crossref","first-page":"2081415","DOI":"10.1080\/2162402X.2022.2081415","article-title":"CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma","volume":"11","author":"Bexte","year":"2022","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0550","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0555","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0560","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040924","article-title":"PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma","volume":"12","author":"Tamura","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0570","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options","volume":"30","author":"Le Calvez","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189493_bb0575","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010113","article-title":"Checkpoint inhibitors in multiple myeloma: intriguing potential and unfulfilled promises","volume":"14","author":"Alkharabsheh","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0585","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0590","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0595","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0600","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189493_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0610","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1878-0261.13483","article-title":"Neoantigens in cancer immunotherapy: quantity vs. quality","volume":"17","author":"Wolf","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0615","first-page":"217 (4)","article-title":"Mutation position is an important determinant for predicting cancer neoantigens","author":"Capietto","year":"2020","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052594","article-title":"Identification of Neoantigens in Cancer cells as targets for immunotherapy","volume":"23","author":"Okada","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0625","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0630","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/mas.21616","article-title":"Identification of Mhc peptides using mass spectrometry for Neoantigen discovery and Cancer vaccine development","volume":"40","author":"Chen","year":"2021","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.bbcan.2025.189493_bb0635","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","article-title":"Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction","volume":"91","author":"Li","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"34","key":"10.1016\/j.bbcan.2025.189493_bb0640","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0645","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7150\/thno.84291","article-title":"Nanoparticle technology for mRNA: delivery strategy, clinical application and developmental landscape","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0650","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11899-015-0283-0","article-title":"Immunotherapy for multiple myeloma, past, present, and future: monoclonal antibodies, vaccines, and cellular therapies","volume":"10","author":"Karp Leaf","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0655","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0660","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10428190500272473","article-title":"Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"47","author":"Bendandi","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0665","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2020008493","article-title":"A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma","volume":"139","author":"Qazilbash","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189493_bb0670","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1182\/blood.V128.22.4548.4548","article-title":"Randomized phase II trial of combination Idiotype vaccine and anti-CD3\/anti-CD28 Costimulated autologous T cells in patients with multiple myeloma post-autotransplantation","volume":"128","author":"Qazilbash","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0675","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00262-015-1703-7","article-title":"Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study","volume":"64","author":"McCann","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189493_bb0680","first-page":"11 (7)","article-title":"Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma","author":"Lebel","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0685","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/1535-7163.MCT-21-0220","article-title":"The road to personalized myeloma medicine: patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy","volume":"21","author":"Puttemans","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0690","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41232-024-00329-2","article-title":"Identification of cancer-specific cell surface targets for CAR-T cell therapy","volume":"44","author":"Hosen","year":"2024","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.bbcan.2025.189493_bb0695","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-cancerbio-061421-014236","article-title":"Next-generation therapies for multiple myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Annu Rev Cancer Biol"},{"issue":"26","key":"10.1016\/j.bbcan.2025.189493_bb0700","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood.2024025655","article-title":"Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy","volume":"145","author":"Carolyn","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bbcan.2025.189493_bb0705","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0710","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/leu.2014.159","article-title":"A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients","volume":"29","author":"Bae","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.13245","article-title":"Phase I\/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients","volume":"169","author":"Carmon","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0720","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-013-1438-2","article-title":"Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0725","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/bloodadvances.2021005941","article-title":"Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant","volume":"6","author":"Chung","year":"2022","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0730","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.27225","article-title":"Soluble B-cell maturation antigen in multiple myeloma","volume":"99","author":"Costa","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0735","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41375-019-0540-7","article-title":"BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications","volume":"34","author":"Jooeun","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2025.189493_bb0740","article-title":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma","author":"Debasmita","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0745","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"Gamma-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb0750","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-024-03913-0","article-title":"Targeting BCMA in multiple myeloma: designs, challenges, and future directions","volume":"74","author":"Hu","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0755","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"Gamma-secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189493_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/cells14141077","article-title":"Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma","volume":"14","author":"Tedder","year":"2025","journal-title":"Cells"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189493_bb0765","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"36","key":"10.1016\/j.bbcan.2025.189493_bb0770","doi-asserted-by":"crossref","DOI":"10.4028\/b-fVvR5S","article-title":"Dual adjuvant-loaded peptide antigen self-assembly potentiates dendritic cell-mediated tumor immunotherapy","volume":"11","author":"Kim","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bbcan.2025.189493_bb0775","doi-asserted-by":"crossref","first-page":"1548979","DOI":"10.3389\/fimmu.2025.1548979","article-title":"In-depth analysis of the safety of CAR-T cell therapy for solid tumors","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0780","article-title":"Targeting BCMA in multiple myeloma: a comprehensive review of immunotherapeutic strategies and clinical outcomes","volume":"33","author":"Chan","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0785","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/2326-6066.CIR-22-0434","article-title":"Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naive multiple myeloma","volume":"10","author":"Welters","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2025.189493_bb0790","article-title":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens","author":"Rieger","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0795","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12967-024-05345-x","article-title":"Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens","volume":"22","author":"Ravn Berg","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189493_bb0800","doi-asserted-by":"crossref","first-page":"1255799","DOI":"10.3389\/fimmu.2023.1255799","article-title":"Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0805","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived Neoantigen-specific T-cell responses in multiple myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0810","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","author":"Miller","year":"2017","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0815","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb0820","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189493_bb0825","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","article-title":"Randomized phase II trial of dendritic cell\/myeloma fusion vaccine with Lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401","volume":"29","author":"Chung","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189493_bb0830","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189493_bb0835","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1089\/10430349950016762","article-title":"RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization","volume":"10","author":"Zhou","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbcan.2025.189493_bb0840","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679344","article-title":"From COVID-19 to Cancer mRNA vaccines: moving from bench to Clinic in the Vaccine Landscape","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0845","first-page":"169","article-title":"Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy","volume":"26","author":"Su","year":"2023","journal-title":"Bioact Mater"},{"key":"10.1016\/j.bbcan.2025.189493_bb0850","doi-asserted-by":"crossref","first-page":"1306025","DOI":"10.3389\/fimmu.2023.1306025","article-title":"From rejection to the Nobel prize: Kariko and Weissman\u2019s pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology","volume":"14","author":"Bansal","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0855","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189493_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/cells14141106","article-title":"Circular RNAs as targets for developing anticancer therapeutics","volume":"14","author":"Jeoung","year":"2025","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb0865","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7662","key":"10.1016\/j.bbcan.2025.189493_bb0870","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb0875","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41592-020-0867-z","article-title":"T cell antigen discovery","volume":"18","author":"Joglekar","year":"2021","journal-title":"Nat. Methods"},{"issue":"6841","key":"10.1016\/j.bbcan.2025.189493_bb0880","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/35082583","article-title":"Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction","volume":"411","author":"Ochsenbein","year":"2001","journal-title":"Nature"},{"issue":"581","key":"10.1016\/j.bbcan.2025.189493_bb0885","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0895","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/14760584.2023.2282065","article-title":"Have mRNA vaccines sentenced DNA vaccines to death?","volume":"22","author":"Cagigi","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.bbcan.2025.189493_bb0900","first-page":"11 (9)","article-title":"Efficacy, immunogenicity, and safety of COVID-19 vaccines in patients with autoimmune diseases: a systematic review and Meta-analysis","author":"Widhani","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbcan.2025.189493_bb0905","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189493_bb0910","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202201095","article-title":"Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system","volume":"34","author":"Pattipeiluhu","year":"2022","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb0915","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.7150\/thno.71760","article-title":"Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy","volume":"12","author":"Shi","year":"2022","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0920","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden Lindsey","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26971","article-title":"The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases","volume":"10","author":"Deyhimfar","year":"2024","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0930","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s12032-025-02923-x","article-title":"CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions","volume":"42","author":"Kuttiappan","year":"2025","journal-title":"Med. Oncol."},{"issue":"7823","key":"10.1016\/j.bbcan.2025.189493_bb0935","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"10427","key":"10.1016\/j.bbcan.2025.189493_bb0940","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0945","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell responses to individualized Neoantigen therapy mRNA-4157 (V940) alone or in combination with Pembrolizumab in the phase 1 KEYNOTE-603 study","volume":"14","author":"Gainor Justin","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189493_bb0950","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jconrel.2024.08.017","article-title":"Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity","volume":"374","author":"Luo","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0955","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-021-01310-0","article-title":"Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"7963","key":"10.1016\/j.bbcan.2025.189493_bb0960","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb0965","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418306122","article-title":"Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and beta-elemene combination therapy","volume":"122","author":"Zhu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb0970","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1021\/acsnano.4c14102","article-title":"Reprogramming the Tolerogenic immune response against pancreatic Cancer metastases by lipid nanoparticles delivering a STING agonist plus mutant KRAS mRNA","volume":"19","author":"Xu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbcan.2025.189493_bb0975","article-title":"Identification of tumor antigens and design of mRNA vaccine for colorectal Cancer based on the immune subtype","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2025.189493_bb0980","first-page":"13 (2)","article-title":"Identification of five tumor antigens for development and two immune subtypes for personalized medicine of mRNA vaccines in papillary renal cell carcinoma","author":"Hu","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.bbcan.2025.189493_bb0985","first-page":"438","article-title":"Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics","volume":"23","author":"Yang","year":"2023","journal-title":"Bioact Mater"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb0990","doi-asserted-by":"crossref","first-page":"2120676","DOI":"10.1080\/2162402X.2022.2120676","article-title":"Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness","volume":"11","author":"Barnestein","year":"2022","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb0995","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202201327","article-title":"Multifunctional liposomes remodeling tumor immune microenvironment for tumor Chemoimmunotherapy","volume":"7","author":"Li","year":"2023","journal-title":"Small Methods"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb1000","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005491","article-title":"TGFbeta-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer","volume":"10","author":"Perez-Penco","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb1005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.fmre.2022.03.009","article-title":"Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: beyond tumor antigens","volume":"3","author":"Zhang","year":"2023","journal-title":"Fundam Res"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00262-025-03992-7","article-title":"Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model","volume":"74","author":"Nguyen","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1015","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1020","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-01077-z","article-title":"The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities","author":"Kung","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb1025","article-title":"Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb1030","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ymthe.2024.01.020","article-title":"Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines","volume":"32","author":"Kubara","year":"2024","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb1035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.tips.2024.10.016","article-title":"Advances in cell therapy: progress and challenges in hematological and solid tumors","volume":"45","author":"D\u2019Avanzo","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb1040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb1045","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41417-023-00717-9","article-title":"A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbcan.2025.189493_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217752","article-title":"Cancer mRNA vaccines: clinical application progress and challenges","volume":"625","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002114","article-title":"Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189493_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189493_bb1065","first-page":"13 (2)","article-title":"Therapeutic vaccines for hematological cancers: a scoping review of this immunotherapeutic approach as alternative to the treatment of these malignancies","author":"Mathias","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb1070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071040","article-title":"mRNA-based anti-TCR CDR3 tumour vaccine for T-cell lymphoma","volume":"13","author":"Tusup","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189493_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb1080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","article-title":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","volume":"109","author":"Oh","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2025.189493_bb1085","first-page":"134 (2)","article-title":"CAR T cells for hematological malignancies","author":"Savoldo","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189493_bb1090","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3389\/fimmu.2019.03004","article-title":"Neoantigens in hematological malignancies-ultimate targets for immunotherapy?","volume":"10","author":"Roerden","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102526","article-title":"Therapeutic hurdles in acute myeloid leukemia: leukemic stem cells, inflammation and immune dysfunction","volume":"82","author":"Wang","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb1100","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","article-title":"Current developments in T-cell receptor therapy for acute myeloid leukemia","volume":"9","author":"Gore","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2025.189493_bb1105","first-page":"11 (7)","article-title":"Combination of cancer vaccine with CD122-biased IL-2\/anti-IL-2 ab complex shapes the stem-like effector NK and CD8(+) T cells against tumor","author":"Shimizu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189493_bb1110","first-page":"23 (2)","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions","author":"Verheye","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb1115","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ijc.34209","article-title":"Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients","volume":"152","author":"Zaleska","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb1125","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3324\/haematol.2021.280163","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis","volume":"107","author":"Gagelmann","year":"2022","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2025.189493_bb1130","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1182\/blood-2024-205663","article-title":"Personalized Neoantigen peptide vaccine with or without Lenalidomide for patients with intermediate or high risk smoldering multiple myeloma (SMM) to prevent progression to multiple myeloma (MM)","volume":"144","author":"Patel","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189493_bb1135","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/bloodadvances.2025016513","article-title":"Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstrom macroglobulinemia","volume":"9","author":"Branagan","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2025.189493_bb1140","first-page":"55 (2)","article-title":"Clinical updates of B-cell maturation antigen-targeted therapy in multiple myeloma (MM) and relapsed\/refractory MM (review)","author":"Xing","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb1145","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1007\/s00262-023-03559-4","article-title":"Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents","volume":"72","author":"Del Giudice","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1150","doi-asserted-by":"crossref","first-page":"2473163","DOI":"10.1080\/2162402X.2025.2473163","article-title":"Humanized mouse models of KRAS-mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies","volume":"14","author":"Davola","year":"2025","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-025-01675-5","article-title":"BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting","volume":"18","author":"Zheng","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","article-title":"BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial","volume":"18","author":"Yao","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb1165","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood.2024027362","article-title":"Doubling down on GPRC5D in multiple myeloma","volume":"145","author":"Neri","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189493_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108007","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma","volume":"232","author":"Choi","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189493_bb1180","article-title":"Sanders Matthew.mRNA multipeptide-HLA class II immunotherapy for melanoma","volume":"14","author":"Georgopoulos Apostolos","year":"2025","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb1185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.bbcan.2025.189493_bb1195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bioactmat.2025.01.028","article-title":"Iterative selection of lipid nanoparticle vaccine adjuvants for rapid elicitation of tumoricidal CD8+ T cells","volume":"48","author":"Luo","year":"2025","journal-title":"Bioactive Materials"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb1200","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tips.2021.03.002","article-title":"The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA","volume":"42","author":"Patel","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189493_bb1205","article-title":"Targeted delivery of c(RGDfk)-modified liposomes to bone marrow through in vivo hitchhiking neutrophils for multiple myeloma therapy","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bbcan.2025.189493_bb1210","doi-asserted-by":"crossref","first-page":"1294929","DOI":"10.3389\/fimmu.2023.1294929","article-title":"Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design","volume":"14","author":"Clemente","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1215","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-025-05329-5","article-title":"The challenges and progress of CAR-T cell therapy in the treatment of solid tumors","author":"Cui","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbcan.2025.189493_bb1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114319","article-title":"Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy","volume":"186","author":"Zhang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12935-025-03793-z","article-title":"Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets","volume":"25","author":"Bahmani","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2025.189493_bb1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101286","article-title":"Targeted therapy in acute myeloid leukemia: resistance and overcoming strategy","volume":"83","author":"Song","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb1235","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-20-2839","article-title":"VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival","volume":"27","author":"Fontana","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189493_bb1240","article-title":"Delivery of therapeutic RNA to the bone marrow in multiple myeloma using CD38-targeted lipid nanoparticles","volume":"10","author":"Tarab-Ravski","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bbcan.2025.189493_bb1245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2023.03.041","article-title":"Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses","volume":"357","author":"Pan","year":"2023","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb1250","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41423-025-01306-6","article-title":"Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7\/8 adjuvant for robust protection against heterologous pandemic and endemic viruses","volume":"22","author":"Yoo","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb1255","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10238-022-00878-1","article-title":"Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model","volume":"23","author":"Sokolowska","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bbcan.2025.189493_bb1260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114238","article-title":"SitoC7A-modified lipid nanoparticles for integrated mRNA delivery and targeted STING activation","volume":"387","author":"Qiao","year":"2025","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189493_bb1265","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2025.189493_bb1270","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-025-02232-7","article-title":"Minimal residual disease negativity as the primary goal of multiple myeloma therapy","author":"Cooperrider","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.bbcan.2025.189493_bb1275","article-title":"Durable protective efficiency provide by mRNA vaccines require robust immune memory to antigens and weak immune memory to lipid nanoparticles","volume":"25","author":"Tang","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.bbcan.2025.189493_bb1280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113891","article-title":"Chitosan and mannose-modified dual-functional mRNA-LNP vaccines for robust systemic and mucosal immune responses","volume":"384","author":"Yi","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189493_bb1285","doi-asserted-by":"crossref","first-page":"1447555","DOI":"10.3389\/fimmu.2024.1447555","article-title":"mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or\/and chemotherapy","volume":"15","author":"Gangaev","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.074","article-title":"An mRNA vaccine encoding proteasome-targeted antigen enhances CD8(+) T cell immunity","volume":"381","author":"Ling","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189493_bb1300","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1305","first-page":"486","article-title":"A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety","volume":"38","author":"Bae","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.bbcan.2025.189493_bb1310","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103428","article-title":"Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study","volume":"87","author":"Giles","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb1315","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ymthe.2024.12.032","article-title":"Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions","volume":"33","author":"Kawai","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2025.189493_bb1320","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101983","article-title":"SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study","volume":"59","author":"Hill","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb1325","doi-asserted-by":"crossref","first-page":"706 e701","DOI":"10.1016\/j.jtct.2023.08.008","article-title":"Immunogenicity and safety of booster SARS-CoV-2 mRNA vaccine dose in allogeneic hematopoietic stem cell transplantation recipients","volume":"29","author":"Mittal","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb1330","article-title":"Assessment of reactivity to the administration of the mRNA vaccine after six months of observation","volume":"11","author":"Slomka","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb1335","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1340","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1350","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-024-01109-4","article-title":"Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm","volume":"14","author":"Pawlyn","year":"2024","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189493_bb1355","article-title":"Successful SARS-CoV-2 mRNA vaccination program in allogeneic hematopoietic stem cell transplant recipients-a retrospective single-center analysis","volume":"11","author":"Nikoloudis","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189493_bb1360","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with Cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb1365","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","article-title":"Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma","volume":"22","author":"Paiva","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1370","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-0572","article-title":"Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance","author":"Firestone Ross","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189493_bb1375","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","article-title":"Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1380","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb1385","article-title":"A universal strategy of anti-tumor mRNA vaccine by harnessing \u201coff-the-shelf\u201d immunity","volume":"12","author":"Fu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bbcan.2025.189493_bb1390","article-title":"Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1395","first-page":"4","volume":"8","author":"Fu","year":"2020","journal-title":"DC-Based Vaccines for Cancer Immunotherapy. Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1400","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12967-024-06033-6","article-title":"mRNA vaccines in the context of cancer treatment: from concept to application","volume":"23","author":"Fu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189493_bb1405","doi-asserted-by":"crossref","first-page":"1572407","DOI":"10.3389\/fimmu.2025.1572407","article-title":"Recent advances of chimeric antigen receptor T-cell therapy for acute myeloid leukemia","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189493_bb1410","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189493_bb1415","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70210","article-title":"Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels","volume":"9","author":"Bruins","year":"2025","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189493_bb1420","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41375-024-02237-3","article-title":"Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain\/amp(1q) in multiple myeloma","volume":"38","author":"Cui","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1425","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-024-50932-7","article-title":"Deciphering the genetics and mechanisms of predisposition to multiple myeloma","volume":"15","author":"Went","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1430","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1186\/s12967-025-06899-0","article-title":"Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies","volume":"23","author":"Sierro-Martinez","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189493_bb1435","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101287","article-title":"Practical guidance on the prevention and management of infection in multiple myeloma patients: a case-based approach","volume":"72","author":"Kannan","year":"2025","journal-title":"Blood Rev."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189493_bb1440","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","article-title":"Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189493_bb1445","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172727","article-title":"Safety and efficacy of bispecific antibody treatment in relapsed\/refractory multiple myeloma: a systematic review and Meta-analysis of proportions from clinical trials","volume":"17","author":"Bakogeorgou","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb1450","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-020-0288-3","article-title":"Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma","volume":"10","author":"Bilich","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbcan.2025.189493_bb1455","doi-asserted-by":"crossref","first-page":"1566461","DOI":"10.3389\/fimmu.2025.1566461","article-title":"An mRNA-based workflow validating neo-epitope presentation through HLA-I\/peptide affinity purification","volume":"16","author":"Esprit","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1460","first-page":"13 (4)","article-title":"Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy","author":"Van der Vreken","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189493_bb1465","first-page":"OF1","article-title":"Acquired and selected: tracking antigen escape during T cell-redirecting therapies in multiple myeloma","author":"Kauer","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb1470","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2025.100251","article-title":"Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction","volume":"4","author":"Tian","year":"2025","journal-title":"Cell Insight"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189493_bb1475","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202415389","article-title":"Piperazine-derived bisphosphonate-based Ionizable lipid nanoparticles enhance mRNA delivery to the bone microenvironment","volume":"64","author":"Yoon","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bbcan.2025.189493_bb1480","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123421","article-title":"Cost-effective yet high-performance ionizable lipids for mRNA-lipid nanoparticle vaccines","volume":"323","author":"Gao","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbcan.2025.189493_bb1485","article-title":"Nanoparticle technologies in precision oncology and personalized vaccine development: challenges and advances","volume":"10","author":"Imani","year":"2025","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.bbcan.2025.189493_bb1490","doi-asserted-by":"crossref","first-page":"1383136","DOI":"10.3389\/fimmu.2024.1383136","article-title":"CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma","volume":"15","author":"Moles","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1495","article-title":"Clinical perspective on topical vaccination strategies","volume":"208","author":"Chen","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1500","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s43556-025-00301-7","article-title":"Mucosal immunity and vaccination strategies: current insights and future perspectives","volume":"6","author":"Zhang","year":"2025","journal-title":"Mol Biomed"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189493_bb1505","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189493_bb1510","first-page":"12 (10)","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","author":"Wang","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1515","doi-asserted-by":"crossref","first-page":"1796002","DOI":"10.1080\/2162402X.2020.1796002","article-title":"Trial watch: experimental TLR7\/TLR8 agonists for oncological indications","volume":"9","author":"Frega","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1520","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189493_bb1525","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189493_bb1530","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.2147\/DDDT.S325790","article-title":"CpG Oligodeoxynucleotide developed to activate primate immune responses promotes Antitumoral effects in combination with a Neoantigen-based mRNA Cancer vaccine","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1535","article-title":"Progress update on STING agonists as vaccine adjuvants","volume":"13","author":"Shen","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb1540","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00204-024-03912-1","article-title":"Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model","volume":"99","author":"Ahn","year":"2025","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1545","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"49","key":"10.1016\/j.bbcan.2025.189493_bb1550","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.vaccine.2021.10.050","article-title":"The influence of interval between doses on response to vaccines","volume":"39","author":"Rodrigues","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.bbcan.2025.189493_bb1555","doi-asserted-by":"crossref","first-page":"1330549","DOI":"10.3389\/fimmu.2024.1330549","article-title":"The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study","volume":"15","author":"Almeida","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189493_bb1560","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/cid\/ciae291","article-title":"SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T-cell therapy: a prospective, multicenter","volume":"79","author":"Hill","year":"2024","journal-title":"Observational Study. Clin Infect Dis"},{"key":"10.1016\/j.bbcan.2025.189493_bb1565","doi-asserted-by":"crossref","first-page":"1510942","DOI":"10.3389\/fimmu.2024.1510942","article-title":"SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy","volume":"15","author":"Martac","year":"2024","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189493_bb1570","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178307","article-title":"Comparison of current immunotherapy approaches and novel anti-Cancer vaccine modalities for clinical application","volume":"26","author":"Meade","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1575","doi-asserted-by":"crossref","first-page":"505","DOI":"10.21147\/j.issn.1000-9604.2025.04.03","article-title":"Bridging transplantation and immunotherapy: clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy","volume":"37","author":"Yan","year":"2025","journal-title":"Chin. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189493_bb1580","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ajh.27207","article-title":"Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma","volume":"99","author":"Mao","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbcan.2025.189493_bb1585","article-title":"Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments","volume":"131 Suppl 2 (Suppl 2)","author":"Peipert","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189493_bb1590","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat. Commun."},{"issue":"10396","key":"10.1016\/j.bbcan.2025.189493_bb1595","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(23)01180-7","article-title":"Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing","volume":"402","author":"Wijaya","year":"2023","journal-title":"Lancet"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:34:18Z","timestamp":1781066058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25002355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":319,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0304419X25002355"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189493","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189493"}}